For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 5–9, 2026
Drug pricing and 340B PhRMA sues to block GLOBE. On October 7, PhRMA sued to block the most-favored-nation drug-pricing model…
Blog
New legislation seeks to shuffle the deck chairs on the sinking No Surprises Act
On October 8, Rep. Frank Pallone (D-NJ) introduced the Lower Premiums, Faster Payments Act as a fix for the disastrous No Surprises Act (NSA).
Blog
This week in health care policy: September 28 – October 2, 2026
Drug pricing CMS finalizes GLOBE pilot. On September 30, CMS finalized the Global Benchmark for Efficient Drug Pricing model, a…
Search Posts
Op-Eds
Anatomy of a Chemical Murder
Wal-Mart announced last week that it would stop selling baby bottles made with the chemical bisphenol A, or BPA.
News Release
Are Imports the Solution to High Drug Prices?
With the high cost of pharmaceutical drugs playing a central role in the national debate over health care, many policymakers have endorsed the idea…
Newsletter
Custody Disputes, Food Shortages and Taxi Cab Fares
Over 400 children seized from a polygamous sect in Texas are dispersed to group homes and shelters across the state. Zimbabwe, confronted with high food…
Study
Drug Reimportation’s Dangerous Allure
A Misguided Cost-Control Measure Guaranteed to Harm Patient Care…
Newsletter
The Fed, Biotech Crops and Mortgage Bailouts
Treasury Secretary Henry Paulson officially announces a plan to reform oversight of financial markets. Research into genetically modified crops gets a boost in India. President…
Newsletter
Sarbanes-Oxley, Cancer Drugs and Discrimination Law
The National Law Journal warns that penalties in the Sarbanes-Oxley accounting rules for public companies can extend to individuals and private entities. Drug maker Cephalon…